ArticleScience translational medicine2015
Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury.
Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Infiltrating Monocyte Fate Switch in Retinal Degeneration: From Early Pathology to Late Homeostasis.Research square · 2026Article
- Infiltrating monocytes augment alternative complement activation and exacerbate inherited retinal degeneration in a mouse model.Research square · 2026Article
- Divergence in photoreceptor cell death and neuroinflammation in transvitreal and transscleral subretinal delivery in mice.Journal of inflammation (London, England) · 2025Article
- A simplified protocol to induce hypoxia in a standard incubator: A focus on retinal cells.Experimental eye research · 2023Article
- Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model.Translational vision science & technology · 2023Article
- Article
- Microglia refine developing retinal astrocytic and vascular networks through the complement C3/C3aR axis.Development (Cambridge, England) · 2023Article
- Proteomics profiling of vitreous humor reveals complement and coagulation components, adhesion factors, and neurodegeneration markers as discriminatory biomarkers of vitreoretinal eye diseases.Frontiers in immunology · 2023Article
- Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases.Cellular and molecular life sciences : CMLS · 2022Review
- Necroptosis and Neuroinflammation in Retinal Degeneration.Frontiers in neuroscience · 2022Review
- Mitochondrial quality control protects photoreceptors against oxidative stress in the HCell death & disease · 2021Article
- Retinal Microvasculature Changes After Repair of Macula-off Retinal Detachment Assessed with Optical Coherence Tomography Angiography.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy.Frontiers in immunology · 2020Article
- Microglia and Inflammatory Responses in Diabetic Retinopathy.Frontiers in immunology · 2020Review
- C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa.The Journal of experimental medicine · 2019Article
- Blocking Complement Factor B Activation Reduces Renal Injury and Inflammation in a Rat Brain Death Model.Frontiers in immunology · 2019Article
- The Challenges and Promise of Complement Therapeutics for Ocular Diseases.Frontiers in immunology · 2019Review
- Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy.Scientific reports · 2018Article
- Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study.Translational vision science & technology · 2018Article
- The Alternative Complement System Mediates Cell Death in Retinal Ischemia Reperfusion Injury.Frontiers in molecular neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Degeneration of photoreceptors is a primary cause of vision loss worldwide, making the underlying mechanisms surrounding photoreceptor cell death critical to developing new treatment strategies. Retinal detachment, characterized by the separation of photoreceptors from the underlying retinal pigment epithelium, is a sight-threatening event that can happen in a number of retinal diseases. The detached photoreceptors undergo apoptosis and programmed necrosis. Given that photoreceptors are nondividing cells, their loss leads to irreversible visual impairment even after successful retinal reattachment surgery. To better understand the underlying disease mechanisms, we analyzed innate immune system regulators in the vitreous of human patients with retinal detachment and correlated the results with findings in a mouse model of retinal detachment. We identified the alternative complement pathway as promoting early photoreceptor cell death during retinal detachment. Photoreceptors down-regulate membrane-bound inhibitors of complement, allowing for selective targeting by the alternative complement pathway. When photoreceptors in the detached retina were removed from the primary source of oxygen and nutrients (choroidal vascular bed), the retina became hypoxic, leading to an up-regulation of complement factor B, a key mediator of the alternative pathway. Inhibition of the alternative complement pathway in knockout mice or through pharmacological means ameliorated photoreceptor cell death during retinal detachment. Our current study begins to outline the mechanism by which the alternative complement pathway facilitates photoreceptor cell death in the damaged retina.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.